-
Posted by
Two Blokes Jul 3 -
Filed in
Stock
-
2 views
The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile of Cosentyx\u00ae (secukinumab)1 EAST HANOVER, N.J. , July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx\u00ae (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).
